Incyte | Le Bénéfice D'Exploitation



Operating Profit Changement Date
Acadia Pharmaceuticals USD 19.29M 134.21M 2025-03
Agios Pharmaceuticals USD -106629000 18.41M 2025-03
Alnylam Pharmaceuticals USD 18.08M 123.24M 2025-03
Amgen USD 1.29B 1.02B 2025-03
Biogen USD 311.2M 130.2M 2025-03
BioMarin Pharmaceutical USD 223.89M 62.49M 2025-03
Bristol-Myers Squibb USD 3.41B 2.62B 2025-03
Eli Lilly USD 5.41B 259.6M 2025-03
Exelixis USD 186.86M 23.65M 2025-04
Gilead Sciences USD 2.24B 215M 2025-03
Incyte USD 205.17M 96.34M 2025-03
Ionis Pharmaceuticals USD -146000000 35.18M 2025-03
MacroGenics USD -16587000 70.78M 2024-12
Merck USD 5.87B 1.57B 2025-03
Moderna USD -1050000000 196M 2025-03
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Pfizer USD 3.67B 4.08B 2025-03
PTC Therapeutics USD 970.22M 1.03B 2025-03
Regeneron Pharmaceuticals USD 591.7M 398.5M 2025-03
Sarepta Therapeutics USD -300386000 462.07M 2025-03
Ultragenyx Pharmaceutical USD -142939000 20.66M 2025-03
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Incyte Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.